Abstract

The accumulation of multiple mutations and alterations in the cancer genome underlies the complexity of cancer phenotypes. A consequence of these alterations is the deregulation of various cell-signalling pathways that control cell function. Molecular-profiling studies, particularly DNA microarray analyses, have the potential to describe this complexity. These studies also provide an opportunity to link pathway deregulation with potential therapeutic strategies. This approach, when coupled with other methods for identifying pathway activation, provides an opportunity to both match individual patients with the most appropriate therapeutic strategy and identify potential options for combination therapy.

Author affiliations

1. Andrea H. Bild, Anil Potti and Joseph R. Nevins are at the Duke Institute for Genome Sciences and Policy, Duke University Medical Center, Durham, North Carolina 27710, USA.

Correspondence to: Joseph R. Nevins¹ Email: nevin001@mc.duke.edu

Published online 17 August 2006

MORE ARTICLES LIKE THIS

These links to content published by NPG are automatically generated.